Distinct Metabolic Signatures Distinguish Lung, Colorectal and Ovarian Cancer
Tsiara, I.; Vouzaxaki, E.; Ekström, J.; Rameika, N.; Yang, F.; Jain, A.; Iglesias Alonso, A.; Sjöblom, T.; Globisch, D.
Show abstract
Cancer-related casualties are the most common cause of death worldwide. The discovery of biomarkers is of utmost importance for diagnosis and disease monitoring. Herein, we performed a comprehensive metabolomics biomarker discovery effort in plasma from 615 lung, ovarian and colorectal cancer patients at diagnosis and 95 non-cancerous control subjects. This pan-cancer investigation identified specific panels of metabolites in the entire sample cohort with a high discriminating power and demonstrated by combined ROC AUC values of up to 0.95. The identified metabolites are mainly associated with lipid and amino acid metabolism as well as xenobiotic transformation. These metabolite panels of high predictive power provide new metabolic insights in these cancers and demonstrate the potential of metabolomics for improved diagnosis and monitoring disease progression.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.